Author Affiliations: Division of Cardiology (Dr Jeong) (firstname.lastname@example.org) and Department of Laboratory Medicine (Drs Park and Kim), Gyeongsang National University Hospital, Jinju, Korea.
To the Editor: The results of the Gauging Responsiveness with a VerifyNow assay–Impact on Thrombosis and Safety (GRAVITAS)1 and Clopidogrel and Aspirin Optimal Dose Usage to Reduce Recurrent Events–Seventh Organization to Assess Strategies in Ischemic Syndromes (CURRENT-OASIS 7)2 trials suggested that high-dose clopidogrel after percutaneous coronary intervention (PCI) can exhibit different clinical efficacy according to the study design. CURRENT-OASIS 7 found a reduction in cardiovascular death, myocardial infarction (MI), or stroke at 1 month with double-dose clopidogrel (adjusted hazard ratio [HR], 0.86) while GRAVITAS, after 6 months, did not (HR, 1.01).
Jeong Y, Park Y, Kim I. Standard- vs High-Dose Clopidogrel After Percutaneous Coronary Intervention. JAMA. 2011;305(24):2520–2522. doi:10.1001/jama.2011.842
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: